Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

PURPOSE: The prognosis of patients with unfit or relapsed/refractory (R/R) AML remains poor. Venetoclax (VEN) has been shown to exhibit anti-leukemia stem cell activity; however, few studies have been published on the efficacy and safety of VEN combined with both hypomethylating agents (HMAs) and lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaotong, Zhao, Yanqiu, Li, Qi, Fan, Shengjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276600/
https://www.ncbi.nlm.nih.gov/pubmed/37334144
http://dx.doi.org/10.2147/OTT.S405611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276600/
https://www.ncbi.nlm.nih.gov/pubmed/37334144
http://dx.doi.org/10.2147/OTT.S405611

Ejemplares similares